Citation: | Halinuer Shadekejiang, Dong Jin, Wu Xiongfei, et al. Application progress in classification of puncture biopsy after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(4): 612-618. doi: 10.3969/j.issn.1674-7445.2023.04.020 |
[1] |
Global observatory on donation and transplantation[EB/ OL]. [2023-01-03].
|
[2] |
CHEN CC, LIN WC, LEE CY, et al. Two-year protocol biopsy after kidney transplantation in clinically stable recipients -a retrospective study[J]. Transpl Int, 2021, 34(1): 185-193. DOI: 10.1111/tri.13785.
|
[3] |
陈实, 郭晖. 移植病理学[M]. 北京: 人民卫生出版社, 2009.
|
[4] |
NAKAGAWA K, TSUCHIMOTO A, UEKI K, et al. Significance of revised criteria for chronic active T cellmediated rejection in the 2017 Banff classification: surveillance by 1-year protocol biopsies for kidney transplantation[J]. Am J Transplant, 2021, 21(1): 174-185. DOI: 10.1111/ajt.16093.
|
[5] |
郭晖, 陈刚. Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用[J]. 器官移植, 2021, 12(1): 15-22. DOI: 10.3969/j.issn.1674-7445.2021.01.003.
GUO H, CHEN G. The origin and development of Banff classification on allograft pathology and its effects in promoting organ transplantation[J]. Organ Transplant, 2021, 12(1): 15-22. DOI: 10.3969/j.issn.1674-7445.2021.01.003.j.issn.1674-7445.2021.01.003.
|
[6] |
HU XJ, ZHENG J, LI Y, et al. Prediction of kidney transplant outcome based on different DGF definitions in Chinese deceased donation[J]. BMC Nephrol, 2019, 20(1): 409. DOI: 10.1186/s12882-019-1557-x.
|
[7] |
MEZZOLLA V, PONTRELLI P, FIORENTINO M, et al. Emerging biomarkers of delayed graft function in kidney transplantation[J]. Transplant Rev (Orlando), 2021, 35(4): 100629. DOI: 10.1016/j.trre.2021.100629.
|
[8] |
CASTRO FILHO JBS, POMPEO JC, MACHADO RB, et al. Delayed graft function under the microscope: surveillance biopsies in kidney transplantation[J]. Transpl Int, 2022, 35: 10344. DOI: 10.3389/ti.2022.10344.
|
[9] |
KASISKE BL, ZEIER MG, CHAPMAN JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary[J]. Kidney Int, 2010, 77(4): 299-311. DOI: 10.1038/ki.2009.377.
|
[10] |
BIA M, ADEY DB, BLOOM RD, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Kidney Dis, 2010, 56(2): 189-218. DOI: 10.1053/j.ajkd.2010.04.010.
|
[11] |
FAVI E, JAMES A, PULIATTI C, et al. Utility and safety of early allograft biopsy in adult deceased donor kidney transplant recipients[J]. Clin Exp Nephrol, 2020, 24(4): 356-368. DOI: 10.1007/s10157-019-01821-7.
|
[12] |
CHERUKURI A, MEHTA R, SOOD P, et al. Early allograft inflammation and scarring associate with graft dysfunction and poor outcomes in renal transplant recipients with delayed graft function: a prospective single center cohort study[J]. Transpl Int, 2018, 31(12): 1369-1379. DOI: 10.1111/tri.13318.
|
[13] |
HATOUM HH, PATEL A, VENKAT KK. The utility of serial allograft biopsies during delayed graft function in renal transplantation under current immunosuppressive regimens[J]. ISRN Nephrol, 2014: 292305. DOI: 10.1155/2014/292305.
|
[14] |
GUETTA O, OSYNTSOV A, RAHAMIMOV R, et al. The role of early sequential biopsies in delayed renal graft function of transplanted kidney is reduced in modern immunosuppression era[J]. Nephron, 2023, 147(3/4): 127-133. DOI: 10.1159/000525912.
|
[15] |
KASISKE BL, ANDANY MA, DANIELSON B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure[J]. Am J Kidney Dis, 2002, 39(4): 762-768. DOI: 10.1053/ajkd.2002.31996.
|
[16] |
ZHANG Q, RUDOLPH B, CHOI M, et al. The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective single-center cohort study[J]. Transpl Int, 2021, 34(2): 259-271. DOI: 10.1111/tri.13787.
|
[17] |
PARAJULI S, SWANSON KJ, ALSTOTT J, et al. Transplant kidney biopsy for proteinuria with stable creatinine: findings and outcomes[J]. Clin Transplant, 2021, 35(10): e14436. DOI: 10.1111/ctr.14436.
|
[18] |
HALIMI JM. Low-grade proteinuria and microalbuminuria in renal transplantation[J]. Transplantation, 2013, 96(2): 121-130. DOI: 10.1097/TP.0b013e31828719fb.
|
[19] |
NAESENS M, LERUT E, EMONDS MP, et al. Proteinuria as a noninvasive marker for renal allograft histology and failure: an observational cohort study[J]. J Am Soc Nephrol, 2016, 27(1): 281-292. DOI: 10.1681/asn.2015010062.
|
[20] |
MASSY ZA, GUIJARRO C, WIEDERKEHR MR, et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors[J]. Kidney Int, 1996, 49(2): 518-524. DOI: 10.1038/ki.1996.74.
|
[21] |
赵明辉. 肾脏病临床概论[M]. 2版. 北京: 北京大学医学出版社, 2021: 668-692.
|
[22] |
RUSH D, NICKERSON P, GOUGH J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study[J]. J Am Soc Nephrol, 1998, 9(11): 2129-2134. DOI: 10.1681/asn.V9112129.
|
[23] |
ROBERTS IS, REDDY S, RUSSELL C, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation[J]. Transplantation, 2004, 77(8): 1194-1198. DOI: 10.1097/01.tp.0000118905.98469.91.
|
[24] |
NANKIVELL BJ, CHAPMAN JR. The significance of subclinical rejection and the value of protocol biopsies[J]. Am J Transplant, 2006, 6(9): 2006-2012. DOI: 10.1111/j.1600-6143.2006.01436.x.
|
[25] |
METTER C, TORREALBA JR. Pathology of the kidney allograft[J]. Semin Diagn Pathol, 2020, 37(3): 148-153. DOI: 10.1053/j.semdp.2020.03.005.
|
[26] |
HUANG Y, FARKASH E. Protocol biopsies: utility and limitations[J]. Adv Chronic Kidney Dis, 2016, 23(5): 326-331. DOI: 10.1053/j.ackd.2016.09.002.
|
[27] |
SZEDERKÉNYI E, IVÁNYI B, MORVAY Z, et al. Treatment of subclinical injuries detected by protocol biopsy improves the long-term kidney allograft function: a single center prospective randomized clinical trial[J]. Transplant Proc, 2011, 43(4): 1239-1243. DOI: 10.1016/j.transproceed.2011.03.078.
|
[28] |
RUSH D, ARLEN D, BOUCHER A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study[J]. Am J Transplant, 2007, 7(11): 2538-2545. DOI: 10.1111/j.1600-6143.2007.01979.x.
|
[29] |
BUEHRIG CK, LAGER DJ, STEGALL MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy[J]. Kidney Int, 2003, 64(2): 665-673. DOI: 10.1046/j.1523-1755.2003.00103.x.
|
[30] |
MEHTA R, CHERIKH W, SOOD P, et al. Kidney allograft surveillance biopsy practices across US transplant centers: a UNOS survey[J]. Clin Transplant, 2017, 31(5). DOI: 10.1111/ctr.12945.
|
[31] |
SCHWARZ A, GWINNER W, HISS M, et al. Safety and adequacy of renal transplant protocol biopsies[J]. Am J Transplant, 2005, 5(8): 1992-1996. DOI: 10.1111/j.1600-6143.2005.00988.x.
|
[32] |
FURNESS PN, PHILPOTT CM, CHORBADJIAN MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates[J]. Transplantation, 2003, 76(6): 969-973. DOI: 10.1097/01.Tp.0000082542.99416.11.
|
[33] |
LOUPY A, MENGEL M, HAAS M. Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics[J]. Kidney Int, 2022, 101(4): 678-691. DOI: 10.1016/j.kint.2021.11.028.
|
[34] |
MENGEL M, LOUPY A, HAAS M, et al. Banff 2019 meeting report: molecular diagnostics in solid organ transplantation-consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation[J]. Am J Transplant, 2020, 20(9): 2305-2317. DOI: 10.1111/ajt.16059.
|
[35] |
VAROL H, ERNST A, CRISTOFERI I, et al. Feasibility and potential of transcriptomic analysis using the nanostring ncounter technology to aid the classification of rejection in kidney transplant biopsies[J]. Transplantation, 2023, 107(4): 903-912. DOI: 10.1097/tp.0000000000004372.
|
[36] |
SMITH RN, ROSALES IA, TOMASZEWSKI KT, et al. Utility of Banff Human Organ Transplant gene panel in human kidney transplant biopsies[J]. Transplantation, 2023, 107(5): 1188-1199. DOI: 10.1097/tp.0000000000004389.
|
[37] |
VAN BAARDWIJK M, CRISTOFERI I, JU J, et al. A decentralized kidney transplant biopsy classifier for transplant rejection developed using genes of the BanffHuman Organ Transplant panel[J]. Front Immunol, 2022, 13: 841519. DOI: 10.3389/fimmu.2022.841519.
|
[38] |
SMITH RN. In-silico performance, validation, and modeling of the Nanostring Banff Human Organ Transplant gene panel using archival data from human kidney transplants[J]. BMC Med Genomics, 2021, 14(1): 86. DOI: 10.1186/s12920-021-00891-5.
|
[39] |
ROSALES I A, MAHOWALD G K, TOMASZEWSKI K, et al. Banff Human Organ Transplant transcripts correlate with renal allograft pathology and outcome: importance of capillaritis and subpathologic rejection[J]. J Am Soc Nephrol, 2022, 33(12): 2306-2319. DOI: 10.1681/asn.2022040444.
|
[40] |
SWANSON KJ, AZIZ F, GARG N, et al. Role of novel biomarkers in kidney transplantation[J]. World J Transplant, 2020, 10(9): 230-255. DOI: 10.5500/wjt.v10.i9.230.
|
[41] |
王策. 蛋白质组学在肾移植急性排斥反应标志物筛选中的应用进展[J]. 医学分子生物学杂志, 2022, 19(6): 514-517. DOI: 10.3870/j.issn.1672-8009.2022.06.013.
WANG C. Application of proteomics in screening markers of acute rejection in renal transplantation[J]. J Med Mol Biol, 2022, 19(6): 514-517. DOI: 10.3870/j.issn.1672-8009.2022.06.013.j.issn.1672-8009.2022.06.013.
|
[42] |
朱亚香, 赵帅林, 杨关印, 等. 移植肾急性排斥反应生物学标记物的研究进展[J] 吉林大学学报(医学版), 2019, 45(5): 1182-1187. DO1: 10.13481/j.1671-587x.20190536. doi: 10.13481/j.1671-587x.20190536
ZHU YX, ZHAO SL, YANG GY, et al. Research progress in biomarkers of acute allograft rejection in kidney transplantation[J]. J Jilin Univ (Med Edit), 2019, 45(5): 1182-1187. DOI: 10.13481/j.1671-587x.20190536.
|
[43] |
HIRT-MINKOWSKI P, HANDSCHIN J, STAMPF S, et al. Randomized trial to assess the clinical utility of renal allograft monitoring by urine CXCL10 chemokine[J]. J Am Soc Nephrol, 2023, DOI: 10.1681/AS.0000000000060[Epubaheadofprint].
|
[44] |
HO J, SCHAUB S, JACKSON AM, et al. Multicenter validation of a urine CXCL10 assay for noninvasive monitoring of renal transplants[J]. Transplantation, 2023, 107(7): 1630-1641. DOI: 10.10970P0000000000554.
|
[45] |
JEON HJ, LEE JG, KIM K, et al. Peripheral blood transcriptome analysis and development of classification model for diagnosing antibody-mediated rejection vs accommodation in ABO-incompatible kidney transplant[J]. Am J Transplant, 2020, 20(1): 112-124. DOI: 10.1111/ajt.15553.
|
[46] |
杨洋, 张健, 林俊. 供者来源性细胞游离DNA在肾移植诊疗中的研究进展与应用[J]. 器官移植, 2022, 13(4): 455-462. DOI: 10.3969/j.issn.1674-7445.2022.04.007.
YANG Y, ZHANG J, LIN J. Research progress and application of donor-derived cell-free DNA in diagnosis and treatment of kidney transplantation[J]. Organ Transplant, 2022, 13(4): 455-462. DOI: 10.3969/j.issn.1674-7445.2022.04.007.j.issn.1674-7445.2022.04.007.
|
[47] |
ZHANG W, YI Z, KEUNG KL, et al. A peripheral blood gene expression signature to diagnose subclinical acute rejection[J]. J Am Soc Nephrol, 2019, 30(8): 1481-1494. DOI: 10.1681/asn.2018111098.
|
[48] |
PARK S, GUO K, HEILMAN RL, et al. Combining blood gene expression and cellfree DNA to diagnose subclinical rejection in kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2021, 16(10): 1539-1551. DOI: 10.2215/cjn.05530421.
|
[49] |
郑瑾, 薛武军. 肾移植新兴生物标志物之研究进展[J]. 器官移植, 2023, 14(2): 194-200. DOI: 10.3969/j.issn.1674-7445.2023.02.003.
ZHENG J, XUE WJ. Research progress on emerging biomarkers in kidney transplantation[J]. Organ Transplant, 2023, 14(2): 194-200. DOI: 10.3969/j.issn.1674-7445.2023.02.003.
|